spacer
home > pmps > winter 2003 > dry powder inhalers - the best alternative drug delivery method?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Dry Powder Inhalers - The Best Alternative Drug Delivery Method?

Delivering drugs directly to the lungs has long been known to have particular benefits for treating pulmonary conditions such as asthma and chronic obstructive pulmonary disease (COPD). By delivering drugs straight to the diseased tissues it is possible to improve the effectiveness of the treatment whilst minimising the drug side effects. Recently, efforts have been made to use the pulmonary drug delivery route to treat a wider range of conditions, including non-pulmonary conditions such as diabetes. However, despite the fact that the average human breathes 25 times every minute, successfully delivering repeatable levels of drug deep into the lungs is a significant challenge.

For a drug particle to have a reasonable chance of being inhaled it needs to have an aerodynamic diameter smaller than five microns and it needs to be inhaled by the patient at the start of their inhalation. Larger particles will end up remaining in the patient's mouth or on the back of their throat, and particles inhaled at the end of the patient's inhalation stroke will remain in the entrance to the lungs or will be exhaled.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jon Tuckwell, Head of Drug Delivery at Cambridge Consultants

Jon Tuckwell is Head of the drug delivery business at Cambridge Consultants. Jon's experience includes working on a wide variety of drug delivery devices including needleless injectors, micro-infusion pumps and five pulmonary inhalers. In the last year Jon has led teams of engineers and scientists to develop two novel MDI technologies designed to overcome the common challenges with pMDIs. Jon has a Masters degree in Mechanical Engineering from Cambridge University.

spacer
Jon Tuckwell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: itís where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on todayís hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement